Open Orphan has announced a new challenge study contract win for Influenza with a US biotechnology company. This is further evidence of the Group's ability to convert the existing pipeline and develop new business to drive significant earnings upgrades over the next 12 months. We anticipate more news flow over the coming months which enhances the earnings power of the business and more than supports our reiterated buy recommendation.
05 Nov 2020
Open Orphan* - New Influenza Challenge Study Contract
hVIVO plc (OPORF:OTC), 0 | hVIVO plc (HVO:LON), 28.2 | hVIVO plc (CRO:FRA), 0 | hVIVO plc (HVO:DUB), 0
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Open Orphan* - New Influenza Challenge Study Contract
hVIVO plc (OPORF:OTC), 0 | hVIVO plc (HVO:LON), 28.2 | hVIVO plc (CRO:FRA), 0 | hVIVO plc (HVO:DUB), 0
- Published:
05 Nov 2020 -
Author:
Andrew Simms -
Pages:
5
Open Orphan has announced a new challenge study contract win for Influenza with a US biotechnology company. This is further evidence of the Group's ability to convert the existing pipeline and develop new business to drive significant earnings upgrades over the next 12 months. We anticipate more news flow over the coming months which enhances the earnings power of the business and more than supports our reiterated buy recommendation.